Merus (MRUS) Investor Presentation - Slideshow

2 Oncology-focused Company Developing Multispecific Antibody Therapies Bispecific and trispecific cancer therapeutic candidates in the human IgG format Common light chain format permits broad, high throughput evaluation of Biclonics® and Triclonics®, to develop clinical stage assets with potential for meaningful clinical activity in patients 1 Schram et al., ASCO 2022, efficacy data cutoff April 12, 2022 and safety data cutoff January 12, 2022 2 Hollebecque et al., AACR-NCI-EORTC 2021, data cutoff August 9, ...